KRd showed superior PFS and deeper responses compared to VRd in newly diagnosed multiple myeloma patients, achieving higher complete response and MRD-negativity rates. The trial demonstrated ...

Darzalex Faspro reduced the risk of disease progression to active multiple myeloma or death by 51% compared with active monitoring. The Food and Drug Administration (FDA) has approved Darzalex Faspro ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression. At the 22nd International Myeloma Society annual ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...

The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) ...

MajesTEC-9 is the second positive Phase 3 study to support TECVAYLI ® regimens as a potential new standard of care as early as first relapse RARITAN, N.J., Jan. 14, 2026 /PRNewswire/ -- Johnson & ...

TORONTO -- For some patients with multiple myeloma and their physicians, progression-free survival (PFS) is just as important as overall survival (OS), according to results from a cross-sectional ...

Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

How Does Blenrep Work for Multiple Myeloma? Blenrep is an antibody-drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs contain two parts, a protein called an antibody and an ...